According to The Irish Times, medical technology company Medtronic has developed a new therapy for high blood pressure that could be a significant breakthrough in the treatment of the condition. The therapy, known as renal denervation, involves using radiofrequency energy to disrupt the nerves in the kidneys that contribute to high blood pressure. This minimally invasive procedure has shown promising results in clinical trials, with patients experiencing a significant reduction in blood pressure levels.
The development of this therapy is particularly significant for Medtronic’s Galway plant in Ireland, as it is the company’s global center for the development and manufacture of renal denervation products. The success of this therapy could lead to increased demand for Medtronic’s products, resulting in a boost for the Galway plant and potentially creating new job opportunities in the region.
Renal denervation has the potential to revolutionize the treatment of high blood pressure, which affects millions of people worldwide. If approved for widespread use, this therapy could provide an alternative to medication for managing blood pressure and potentially reduce the risk of associated complications such as heart disease and stroke.
